Organic light emitting diodes (devices) or OLEDs are monolithic solid-state devices that typically consist of a series of organic thin films sandwiched between two thin film conductive electrodes. It is a display technology used in many electronic devices, such as smartphones, televisions, and wearables. In an OLED display, each pixel is made up of organic compounds that emit light when an electric current passes through them. Unlike traditional LCD displays, this eliminates the need for a backlight. As a result, OLED displays can achieve deeper blacks and higher contrast ratios, leading to vibrant and more realistic images.
Verona Pharma's Ensifentrine was accepted for NDA Review by FDA for chronic obstructive pulmonary disease (COPD) maintenance treatment. COPD is used to describe chronic lung diseases, encompassing emphysema, and chronic bronchitis. Phase 3 ENHANCE trials demonstrated Ensifentrine's efficacy and safety, showing significant improvements in lung function, symptom endpoints, and reducing the rate and risk of COPD exacerbations. Ensifentrine offers a novel mechanism of action. It is a dual inhibitor of phosphodiesterase 3 (PDE3) and phosphodiesterase 4 (PDE4); it is also an activator of the cystic fibrosis transmembrane conductance regulator (CFTR).